Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic ...

Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in ...

Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate ...

Treanda) plus rituximab (HR 0.54, 95% CI 0.39-0.75, P=0.0002), reported Jeff Sharman, MD, of Willamette Valley Cancer Institute and Research Center and U.S. Oncology Research in Eugene ...